Barclays reaffirmed their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research report sent to investors on Friday morning. They currently have a GBX 1,950 ($25.48) target price on the stock.
A number of other equities research analysts have also commented on the stock. Peel Hunt reaffirmed an add rating on shares of Hikma Pharmaceuticals in a research note on Thursday. Citigroup reaffirmed a buy rating and issued a GBX 2,250 ($29.40) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, October 30th. JPMorgan Chase & Co. reaffirmed a neutral rating and issued a GBX 1,050 ($13.72) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, August 21st. Finally, Numis Securities reaffirmed a hold rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of GBX 1,459 ($19.06).
Shares of LON:HIK traded down GBX 170.50 ($2.23) during trading on Friday, reaching GBX 1,854.50 ($24.23). The stock had a trading volume of 1,517,297 shares, compared to its average volume of 822,138. Hikma Pharmaceuticals has a 52 week low of GBX 814.20 ($10.64) and a 52 week high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Featured Article: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.